Ibudilast is an investigational medicinal product that is approved in Japan by the Pharmaceutical and Medical Devices Agency (PMDA) yet not by the US FDA.
This research chemical is believed to possess anti-inflammatory properties that can be beneficial for treating bronchial asthma, cerebrovascular disorders, and potentially other conditions like MS and ALS. Its ability to inhibit specific enzymes involved in inflammation makes it a valuable research subject in promoting health and managing various inflammatory-related conditions.
Since the chemical compound is not FDA-approved, buy Ibudilast for research purposes only.
Ibudilast Product Details
Ibudilast is a chemical product that has shown beneficial effects in various medical conditions. Kyorin Pharmaceutical Co. Ltd, is actively engaged in studying Ibudilast to determine its efficacy and potential health benefits.
Primarily being studied to treat bronchial asthma and cerebrovascular disorders, Ibudilast acts as an inhibitor of certain enzymes, contributing to its therapeutic benefits.
Moreover, Ibudilast has been investigated as a potential treatment for other conditions, such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). In MS, Ibudilast’s anti-inflammatory properties may help modulate the immune response, reducing the frequency and severity of relapses. For ALS, Ibudilast’s anti-inflammatory effects may slow down the progression of the disease by protecting motor neurons from damage.
- CAS Number: 50847-11-5
- Molar Mass: 314.41 g/mol
- Chemical Formula: C14H18N2O
- IUPAC Name: 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
- Also known by Synonyms: Ketas, MN-166, AV411, 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
Key Features of Ibudilast for Sale
- 98% Purity
- Sold for research purposes only
Potential Benefits of Ibudilast
Possible Treatment of Bronchial Asthma
Clinical trials have shown that Ibudilast exhibits anti-inflammatory properties, which can help alleviate the symptoms of bronchial asthma. A study conducted on patients with bronchial asthma demonstrated that Ibudilast significantly reduced airway hyperresponsiveness and improved lung function when compared to a placebo group. [R] [R]
Management of Cerebrovascular Disorders
Laboratory research and clinical studies have indicated that Ibudilast has potential benefits for cerebrovascular disorders. In a double-blind study involving patients with cerebral infarction, Ibudilast demonstrated a reduction in inflammatory markers and an improvement in blood flow to the brain. [R] [R]
Potential for Amyotrophic Lateral Sclerosis (ALS) Treatment
Research conducted by Neurologic Associates has shown that Ibudilast has neuroprotective effects and can slow down the progression of ALS. A clinical study involving ALS patients treated with Ibudilast showed a significant reduction in the decline of motor function compared to a placebo group. [R]
Ibudilast is commonly abbreviated as an anti-inflammatory medicine. It inhibits certain enzymes involved in inflammation, leading to a reduction in inflammatory responses in the body. Laboratory research has indicated that Ibudilast may suppress the production of pro-inflammatory substances and modulate the immune response. [R]
Safety and Tolerability
Clinical studies have reported that Ibudilast is generally well-tolerated by healthy volunteers and patients. A phase I clinical trial evaluating the safety of Ibudilast in healthy volunteers observed no serious adverse effects or abnormalities in vital signs at various doses. [R]
Disclaimer: The information provided above is based on available research and clinical studies. It is important to consult a doctor or healthcare professional before starting any new treatment or medication. The efficacy and safety of Ibudilast may vary among individuals, and special attention should be given to individual circumstances and medical history.
How It Works
Ibudilast exerts its effects on the human body through a multi-faceted mechanism of action. As a phosphodiesterase (PDE) inhibitor, Ibudilast acts by suppressing the activity of certain PDE enzymes, primarily PDE4 and PDE10. This inhibition leads to increased levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in various cells and tissues. Elevated cAMP and cGMP levels contribute to the therapeutic benefits of Ibudilast in several conditions.
In the context of bronchial asthma, Ibudilast could help alleviate the symptoms by targeting the inflammation of the airways. It acts as an anti-inflammatory agent, reducing the swelling and constriction of the bronchial tubes, thus facilitating easier breathing and improving lung function.
Additionally, Ibudilast has demonstrated potential benefits in cerebrovascular disorders, which are conditions affecting blood vessels in the brain. By inhibiting certain enzymes involved in inflammation, Ibudilast helps to reduce vascular inflammation, which can improve blood flow to the brain and potentially prevent or mitigate damage caused by cerebrovascular disorders.
Furthermore, Ibudilast has been found to affect glial cells in the central nervous system (CNS). It can inhibit the activation and proliferation of microglia and astrocytes, which are involved in neuroinflammation and neurodegenerative processes. By reducing the activation of glial cells, Ibudilast exerts a neuroprotective effect and may slow down the progression of neurologic diseases.
Ibudilast should not be used by certain test subjects, and caution should be exercised when considering its use. The following groups of people should avoid Ibudilast:
Children: Ibudilast has not been extensively studied in children, and its safety and efficacy in pediatric populations have not been established. Therefore, Ibudilast use in children should be avoided unless specifically prescribed by a healthcare professional with expertise in pediatric medicine.
Individuals with specific medical conditions: Individuals with certain medical conditions may require caution and close monitoring when using Ibudilast. This includes individuals with severe liver or kidney impairment, as well as those with a history of drug hypersensitivity or allergic reactions.
Pregnant individuals: The use of Ibudilast during pregnancy is not recommended, as its safety for unborn babies has not been established. Pregnant individuals should consult their healthcare provider before considering the use of Ibudilast or any other medication.
Breastfeeding individuals: Ibudilast may pass into breast milk, and its potential effects on nursing infants are not known. Therefore, breastfeeding individuals should exercise caution and consult their healthcare provider before using Ibudilast. In some cases, alternative treatments or discontinuation of breastfeeding may be advised.
Dosage and concentration: Ibudilast should be used at the exact dosage and concentration prescribed by a healthcare professional. Deviating from the recommended dosage or concentration may lead to inadequate or excessive drug levels in the body, potentially affecting efficacy and safety.
Potential Side Effects
The safety profile of Ibudilast has been generally favorable, but like any research chemical, it may cause adverse reactions in some individuals. Commonly reported side effects of Ibudilast include nausea and dizziness. It is important to follow the prescribed dosage and administration form of Ibudilast to minimize the likelihood of experiencing these side effects.
Ibudilast is not intended for drug abuse, and its supply typically requires a valid prescription and proper payment procedures.
In conclusion, Ibudilast offers several potential benefits in the treatment of various medical conditions. Extensive research, including clinical trials, supports its use in bronchial asthma and cerebrovascular disorders. Clinical trials conducted on both test subjects with bronchial asthma and healthy volunteers have shown significant improvements in lung function and reduced airway hyperresponsiveness when treated with Ibudilast. Similarly, studies involving patients with cerebral infarction have demonstrated enhanced blood flow to the brain and reduced inflammatory markers upon Ibudilast administration.
While Ibudilast’s benefits are compelling, it is crucial to emphasize the importance of obtaining Ibudilast through appropriate channels. As Ibudilast does not belong to the class of approved medicines, it should only be acquired for research purposes alone. The ordering process should involve legitimate pharmaceuticals company or reputable online stores to obtain the best price for Ibudilast.
It is essential to note that the molecular weight, chemical properties, and pharmacological characteristics of Ibudilast, commonly abbreviated as KC 404, should be considered in its production.
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before making a purchase from rcd.bio. By completing your order and submitting payment, you agree to abide by our Terms and Conditions. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If for any reason you are not completely satisfied with the product you receive, please contact us at [email protected]. Our team is dedicated to ensuring customer satisfaction and will be happy to assist you.
PLEASE NOTE: All products offered by rcd.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.